| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 343 |
| 1 | NIVOLUMAB | 318 |
| 2 | IPILIMUMAB | 184 |
| 3 | CARBOPLATIN | 125 |
| 4 | PACLITAXEL | 102 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 89 |
| 6 | ATEZOLIZUMAB | 61 |
| 7 | BEVACIZUMAB | 47 |
| 8 | HYDROCORTISONE | 40 |
| 9 | HYDROCORTISONE CREAM | 40 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TREMELIMUMAB | 22 | 0.0050 |
| 1 | IPILIMUMAB | 184 | 0.0042 |
| 2 | NIVOLUMAB | 318 | 0.0032 |
| 3 | PEMBROLIZUMAB | 343 | 0.0032 |
| 4 | NALDEMEDINE | 5 | 0.0030 |
| 5 | VONOPRAZAN FUMARATE | 16 | 0.0020 |
| 6 | CEMIPLIMAB-RWLC | 4 | 0.0019 |
| 7 | BETAMETHASONE VALERATE FOAM | 8 | 0.0017 |
| 8 | DURVALUMAB | 37 | 0.0017 |
| 9 | ATEZOLIZUMAB | 61 | 0.0015 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Melanocortin 4 Receptor Agonist [EPC] | 3 | 0.0105 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 712 | 0.0072 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 205 | 0.0043 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 42 | 0.0019 |
| 4 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 5 | Opioid Antagonist [EPC] | 1 | 0.0010 |
| 6 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 5 | 0.0008 |
| 7 | Chemokine Receptor Type 4 Interaction [EPC] | 1 | 0.0007 |
| 8 | Platinum-based Drug [EPC] | 179 | 0.0007 |
| 9 | Microtubule Inhibitor [EPC] | 105 | 0.0006 |